Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists

Chemotherapy-Induced Nausea and Vomiting: 5-HT₃ Receptor Antagonists

5-HT3 receptor antagonists, such as dolasetron, granisetron (Kytril), ondansetron (Zofran), and palonosetron (Axoli), are crucial in managing chemotherapy-induced nausea and vomiting (CINV) and postoperative nausea. These drugs selectively block 5-HT3 receptors in the visceral vagal and spinal afferent nerves, chemoreceptor trigger zone, and the vomiting center. They have a rapid onset of action and can be given as a single dose before chemotherapy. Ondansetron and granisetron, in particular,...

Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists

Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists

Neurokinin 1 (NK1) receptors are distributed across the GI tract, vagal afferents, and key CNS regions including the central vomiting center and chemoreceptor trigger zone (CTZ) Chemotherapy agents stimulate enterochromaffin cells in the gastrointestinal (GI) tract to release large amounts of substance P (SP). SP is a neuropeptide released by specific sensory nerves in response to many different stressors, including those in the GI mucosa affected by chemotherapy. SP binds and activates these...

Chemotherapy-Induced Nausea and Vomiting: Cannabinoids

Chemotherapy-Induced Nausea and Vomiting: Cannabinoids

Tetrahydrocannabinol (THC) is a phytocannabinoid that primarily interacts with the CB1 receptor, a type of G protein-coupled receptor (GPCR) predominantly in and around the chemoreceptor trigger zone (CTZ) and emetic center. THC also blocks the serotonin receptor activity in the dorsal vagal complex (DVC) by inhibiting serotonin release. THC exerts its anti-emetic effects through these interactions, which are beneficial for patients undergoing chemotherapy.
Two synthetic agonists of THC,...

Cancer Therapies

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...

Cancer Therapies

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Impact of Covid-19 pandemic on neuro-oncology multidisciplinary tumor board in the pre-vaccine era: the Normandy experience.

Neuro-Chirurgie·2023

Same author

Impact of EGFR<sup>A289T/V</sup> mutation on relapse pattern in glioblastoma.

ESMO open·2022

Same author

Usefulness of circulating tumor DNA from cerebrospinal fluid in recurrent high-grade glioma.

Revue neurologique·2022

Same author

[Strategy for the practice of digestive and oncologic surgery in COVID-19 epidemic situation].

Journal de chirurgie viscerale·2020

Same author

Strategy for the practice of digestive and oncological surgery during the Covid-19 epidemic.

Journal of visceral surgery·2020

Same author

Impact of locoregional irradiation in patients with upfront metastatic head and neck squamous cell carcinoma.

Oral oncology·2019

Search research articles

Related Experiment Video

Updated: May 29, 2026

Chemotherapy-induced Vascular Toxicity - Real-time In vivo Imaging of Vessel Impairment

Chemotherapy-induced Vascular Toxicity - Real-time In vivo Imaging of Vessel Impairment

Published on: January 7, 2015

[Chemotherapy and rectal cancer].

P Michel¹, F Di Fiore

¹Unité d'oncologie urodigestive, pôle viscéral, hôpital Charles-Nicolle, CHU de Rouen, Rouen cedex, France. Pierre.michel@chu-rouen.fr

Cancer Radiotherapie : Journal De La Societe Francaise De Radiotherapie Oncologique

|September 3, 2011

Summary

Chemotherapy does not improve survival for rectal cancer but significantly reduces local recurrence when combined with radiation. Achieving a complete pathological response is a key favorable prognostic factor.

More Related Videos

Acupoint Application Combined with Acupressure as an Adjunctive Therapy for Chemotherapy-Induced Nausea and Vomiting

Acupoint Application Combined with Acupressure as an Adjunctive Therapy for Chemotherapy-Induced Nausea and Vomiting

Published on: June 21, 2024

Pretargeted Radioimmunotherapy Based on the Inverse Electron Demand Diels-Alder Reaction

Pretargeted Radioimmunotherapy Based on the Inverse Electron Demand Diels-Alder Reaction

Published on: January 29, 2019

Related Experiment Videos

Last Updated: May 29, 2026

Chemotherapy-induced Vascular Toxicity - Real-time In vivo Imaging of Vessel Impairment

Chemotherapy-induced Vascular Toxicity - Real-time In vivo Imaging of Vessel Impairment

Published on: January 7, 2015

Acupoint Application Combined with Acupressure as an Adjunctive Therapy for Chemotherapy-Induced Nausea and Vomiting

Acupoint Application Combined with Acupressure as an Adjunctive Therapy for Chemotherapy-Induced Nausea and Vomiting

Published on: June 21, 2024

Pretargeted Radioimmunotherapy Based on the Inverse Electron Demand Diels-Alder Reaction

Pretargeted Radioimmunotherapy Based on the Inverse Electron Demand Diels-Alder Reaction

Published on: January 29, 2019

Area of Science:

Oncology
Gastroenterology

Background:

Rectal cancer treatment often involves a multimodal approach.
The role of chemotherapy in conjunction with radiotherapy is an area of ongoing research.

Purpose of the Study:

To evaluate the impact of chemotherapy on rectal cancer outcomes, particularly local recurrence and survival.
To assess the prognostic significance of complete pathological response.

Main Methods:

Analysis of chemotherapy's effect when given concomitantly with radiotherapy, and before or after radiation.
Review of evidence regarding postoperative chemotherapy and its indications.

Main Results:

Chemotherapy does not increase overall survival time for rectal cancer patients.
Concomitant or sequential chemotherapy with radiotherapy significantly reduces local recurrence risk.
Complete pathological response is a favorable prognostic factor.

Conclusions:

While not improving survival, chemotherapy is crucial for reducing local recurrence in rectal cancer when combined with radiotherapy.
Optimizing complete pathological response rates is a focus of new trials, exploring neoadjuvant chemotherapy strategies.
Postoperative chemotherapy indications are limited and depend on residual disease after neoadjuvant treatment.